| Patient | Sarah Walker |
|---|---|
| Date of birth | 1976-12-23 |
| Identifiers | MRN HR-ET019-SYN; SSN (made up) 000-19-7062 |
| Document date | 2026-08-17 |
| Author | Harriet Okonjo-Bell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review: blood pressure at goal, urine albumin, kidney function, hemoglobin, mood, and the travel season ahead. [S]
Madam Walker returns ten weeks after her preventive visit; the laboratory day was booked before her summer trips, as planned. Her home readings average 123/77 on losartan 100 mg, amlodipine 5 mg and empagliflozin 10 mg. She has had no ankle swelling, dizziness, genital itching or muscle aches. Her mammogram was normal and her HPV test and stool test were negative. Having read about APOL1 testing, she has decided not to have it for now, since it would not change her treatment; she knows it remains available. She plans an autumn of travel and asked what she should watch for on the road. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 123/77 |
| Screening | Mammogram normal; HPV and stool tests negative |
| APOL1 testing | Declined for now, her choice |
| Mood | PHQ-9 3 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness; weight down 3.2 kg since intake |
| Cardiovascular | Negative | No ankle swelling or palpitations |
| Genitourinary | Negative | No burning or genital itching |
| Musculoskeletal | Negative | No muscle aches |
| Psychiatric | Negative | Mood steady |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg oral tablet, one tablet each morning | One tablet each morning, at the same home time when traveling | Oral route | 2026-02-23 to 2026-03-09 | completed | S |
| Losartan 100 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-03-09 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet each morning, with sick-day rules | Oral route | 2026-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-23 | active | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet on the tongue every 8 hours as needed for nausea, for up to two days | Every 8 hours as needed for nausea, up to two days | Oral route | 2026-04-13 to 2026-04-15 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-17 | Body height | 163 | cm | S |
| 2026-08-17 | Body weight | 75.8 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 28.5 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 72 | /min | S |
| 2026-08-17 | Respiratory rate | 16 | /min | S |
| 2026-08-17 | Body temperature | 36.7 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-17 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-17 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-17 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-08-17 | Creatinine [Mass/volume] in Serum or Plasma | 1.3 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-08-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 50 | mL/min/{1.73_m2} | 60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3a | Low | S |
| 2026-08-17 | Albumin/Creatinine [Mass Ratio] in Urine | 128 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 2026-08-17 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-08-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 72; weight 75.8 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Respiratory | Clear |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressure | active | confirmed | I12.9 | S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis. |
| Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6% | active | confirmed | N18.31 | S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease. |
| Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate) | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Viral gastroenteritis after a sales convention, with mild volume depletion and losartan and empagliflozin held under her sick-day rules; no acute kidney injury; resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings) | Every visit | Completed today | 122/76 |
| Self-management | Home blood pressure readings | Two readings morning and evening for seven days to confirm and after each change; then twice a week, travel days included | Completed today | Average 123/77 |
| Examination | Weight and BMI | Every visit | Completed today | 75.8 kg, down 3.2 kg since intake |
| Laboratory | Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 2021, race-free) | Two to four weeks after starting or increasing losartan or empagliflozin; then every six months | Completed today | Potassium 4.8, bicarbonate 25 mmol/L; creatinine 1.30 mg/dL, eGFR 50 |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; about three months after a treatment change; then every six months for G3a A2 | Completed today | 128 mg/g, 56% lower than baseline |
| Laboratory | Hemoglobin | Yearly in CKD G3 | Completed today | 12.6 g/dL |
| Laboratory | Calcium, phosphate and parathyroid hormone | At diagnosis of G3a, then every 6 to 12 months | Due | Normal at diagnosis; repeat at one year |
| Survey | Kidney failure risk equation (4-variable), 2- and 5-year | Yearly for G3 to G5 | Completed today | 5-year risk 1.7% |
| Laboratory | Lipid panel and ALT | 4 to 12 weeks after starting a statin, then yearly | Up to date | LDL 98 mg/dL in April; yearly panel at one year |
| Examination | Fundus examination | Yearly | Due | Dilated examination by an optometrist booked for the autumn |
| Medication safety | Medicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zones | Every visit | Completed today | No ankle swelling, dizziness, genital itching or muscle aches; sick-day card current |
| Medication safety | Vaccination review | Yearly in CKD | Completed today | Hepatitis B dose 2 given today; influenza and COVID-19 due in the autumn; zoster from 50 |
| Self-management | Sodium and diet counseling | Every visit | Completed today | Salt-free seasoning at home; restaurant choices on the road |
| Survey | Depression screen (PHQ-9) | At intake, then yearly | Completed today | PHQ-9 3 |
| Referral | Nephrology review | At diagnosis; then about six months, by video if she prefers | Due | Video review with Dr. Achterberg booked for next month |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023); Adult Immunization Schedule by Age (2026)
Follow-up: Video review with nephrology next month. Influenza and COVID-19 vaccines in the autumn; zoster after her birthday. Review in six months with urine albumin, kidney function, the yearly lipid panel and calcium, phosphate and parathyroid hormone, booked on a home day. Hold losartan and empagliflozin on days of vomiting, diarrhea or not eating. [S]